GI Oncology
Matthew Strickland, MD, discusses the current management of defective mismatch repair in gastroesophageal adenocarcinoma.
Researchers conducted a comprehensive analysis to determine the association between HCC disease stage and prognosis.
RNA biomarkers are not reliant on age-related methylation patterns that may result in test performance variability.
The effects of primary tumor and LN volume on clinical outcomes in ESCC following neoadjuvant CCRT and surgery are unknown.
PRECEDE offers testing for individuals at high risk of pancreatic cancer, with multiple testing sites located globally.
Dr. Rodón Ahnert compares the differences of sacituzumab tirumotecan use in the second- vs third-line setting for patients.
Dr. Goel discusses how his team's liquid biopsy can be used with CA19-9 to boost the accuracy of detecting pancreatic cancer.
Colorectal cancer screening intervals can potentially be extended to 15 years to avoid unnecessary invasive examinations.
Lenvatinib is a common treatment for patients with uHCC, and has been used with pembrolizumab for other diseases.
Pembrolizumab Shows Promise as a First-line Treatment for Advanced Gastric, Gastroesophageal Cancers
The final results from the KEYNOTE-811 trial will determine if Keytruda will receive continued approval from the FDA.
Researchers analyzed the utilization and outcomes of multigene panel GT in patients with PDAC.
Drs. Nataliya Uboha and Christopher Lieu highlight a recent analysis of the KRYSTAL-1 trial for metastatic colorectal cancer.
The TransMet trial was developed to determine the efficacy of chemotherapy with LT compared with chemotherapy alone.
ASCO has issued a companion piece to previously released guidelines addressing commonly asked questions.
HERCESSI was developed by Accord BioPharma, Inc., the US specialty division of Intas Pharmaceuticals Ltd.
A review analyzed 30 meta-analyses to determine the association between pretreatment NLR and immunotherapy outcomes.
The study’s primary end point was objective response rate determined through blinded independent central review.
Dr. Ronan Kelly describes his trial on nivolumab with relatlimab for the treatment of resectable esophageal/GEJ cancer.
Dr. Gulam A. Manji discusses CXCR4 and PD-1 inhibitors and how research has shown a potential benefit of the combination.
Dr. Gulam A. Manji discusses the ARC-8 study on quemliclustat plus gemcitabine/nab-paclitaxel with and without zimberelimab.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.